ERBB2 and breast cancer: Indeed, asymptomatic brain metastases have been found in up to 12% of early-stage ERBB2+ breast cancer, while 25%–50% of patients with metastatic breast cancer (MBC) will develop brain metastases (BM) (Zimmer et al., 2022).